Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-08-14

Clinical Trial Update: Long-Term PF-06651600 for the Treatment of Alopecia Areata [Phase 3]

View source ↗

Summary

Pfizer completed a long-term Phase 3 trial of PF-06651600 for alopecia areata. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PF-06651600 (PF-06651600)

Snippet

Sponsor: Pfizer | Conditions: Alopecia Areata | Phase 3 | Status: COMPLETED | Results posted: 2025-08-14